| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
SY-LB-35 is a bone morphogenetic protein (BMP) receptor agonist that stimulates significant increases in cell number and cell viability in the C2C12 myoblast cell line, and causes shifts towards the S and G2/M phases of the cell cycle.
| ln Vitro |
In the C2C12 myoblast cell line, SY-LB-35 (0.01-1000 μM; 24 hours) can significantly enhance cell viability and number [1]. SY-LB-35 (0.01-10 μM; 30 minutes or 15 minutes) induces nuclear translocation and Smad phosphorylation, leads the cytoplasmic localization of p-Akt in the PI3K/Akt pathway, and increases PI3K phosphorylation in C2C12 cells [1]. C2C12 cells undergo the cell cycle transition into the S and G2/M phases when exposed to SY-LB-35 (0.01-10 μM; 24 hours) [1].
|
|---|---|
| Cell Assay |
Cell Viability Assay [1]
Cell Types: C2C12 Cell Tested Concentrations: 0.01, 0.1, 1, 10, 100 and 1000 μM Incubation Duration: 24 hrs (hours) Experimental Results: Stimulated cell number and cell viability increased Dramatically. Western Blot Analysis[1] Cell Types: C2C12 Cell Tested Concentrations: 0.01, 0.1, 1 and 10 μM Incubation Duration: 30 or 15 minutes Experimental Results: Stimulates Smad phosphorylation and nuclear translocation, activates the PI3K/Akt pathway and directs the cytoplasmic localization of p -Akt, stimulates phosphorylation and activation of PI3K in C2C12 cells. Cell cycle analysis [1] Cell Types: C2C12 cells Tested Concentrations: 0.01, 0.1, 1 and 10 μM Incubation Duration: 24 h Experimental Results: Causes cell cycle to shift to S phase and G2/M phase. |
| References |
| Molecular Formula |
C15H11N3O
|
|---|---|
| Molecular Weight |
249.267342805862
|
| Exact Mass |
249.09
|
| CAS # |
2603461-70-5
|
| PubChem CID |
164885346
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
3
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
19
|
| Complexity |
337
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
N1C2=C(C=C(O)C=C2)C=C1C1NC2=CC=CC=C2N=1
|
| InChi Key |
MIVGVAZQKUNNAM-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H11N3O/c19-10-5-6-11-9(7-10)8-14(16-11)15-17-12-3-1-2-4-13(12)18-15/h1-8,16,19H,(H,17,18)
|
| Chemical Name |
2-(1H-benzimidazol-2-yl)-1H-indol-5-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~401.17 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (10.03 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (10.03 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0117 mL | 20.0586 mL | 40.1171 mL | |
| 5 mM | 0.8023 mL | 4.0117 mL | 8.0234 mL | |
| 10 mM | 0.4012 mL | 2.0059 mL | 4.0117 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
